Success Metrics

Active Trials
3(38%)

Phase Distribution

Ph phase_3
1
13%
Ph phase_2
3
38%
Ph phase_4
1
13%
Ph not_applicable
2
25%

Phase Distribution

0

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution7 total trials
Phase 2Efficacy & side effects
3(42.9%)
Phase 3Large-scale testing
1(14.3%)
Phase 4Post-market surveillance
1(14.3%)
N/ANon-phased studies
2(28.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

8

all time

Status Distribution
Active(8)

Detailed Status

Not yet recruiting5
Recruiting3

Development Timeline

Analytics

Development Status

Total Trials
8
Active
3
Success Rate
N/A
Most Advanced
Phase 4

Trials by Phase

Phase 23 (42.9%)
Phase 31 (14.3%)
Phase 41 (14.3%)
N/A2 (28.6%)

Trials by Status

not_yet_recruiting563%
recruiting338%

Recent Activity

3 active trials
Showing 5 of 8
recruitingphase_2

Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer

NCT07717242
not_yet_recruiting

Tafolecimab in Hyperlipidemia: A Study of Different Dosing Intervals

NCT07712042
not_yet_recruitingphase_3

Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial

NCT07686796
recruitingphase_2

Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

NCT07061535
not_yet_recruitingnot_applicable

INtensive liPid-lowering Therapy for Acute High-risk IntracRanial or Extracranial atheroSclerosis -II (INSPIRES-2)

NCT07341958
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT07717242Phase 2

Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer

Recruiting
NCT07712042

Tafolecimab in Hyperlipidemia: A Study of Different Dosing Intervals

Not Yet Recruiting
NCT07686796Phase 3

Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial

Not Yet Recruiting
NCT07061535Phase 2

Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

Recruiting
NCT07341958Not Applicable

INtensive liPid-lowering Therapy for Acute High-risk IntracRanial or Extracranial atheroSclerosis -II (INSPIRES-2)

Not Yet Recruiting
NCT06683131Phase 4

Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Initiation Before Percutaneous Coronary Intervention on Acute Myocardial Infarction Patients

Not Yet Recruiting
NCT06421298Phase 2

A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.

Recruiting
NCT06096909Not Applicable

Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population

Not Yet Recruiting

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8